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ABSTRACT
Here, we developed a new synthetic lethal strategy for further optimizing the 
eradication of cancer stem cells (CSCs). Briefly, we show that chronic treatment with 
the FDA-approved antibiotic Doxycycline effectively reduces cellular respiration, by 
targeting mitochondrial protein translation. The expression of four mitochondrial 
DNA encoded proteins (MT-ND3, MT-CO2, MT-ATP6 and MT-ATP8) is suppressed, by 
up to 35-fold. This high selection pressure metabolically synchronizes the surviving 
cancer cell sub-population towards a predominantly glycolytic phenotype, resulting 
in metabolic inflexibility. We directly validated this Doxycycline-induced glycolytic 
phenotype, by using metabolic flux analysis and label-free unbiased proteomics. 
Next, we identified two natural products (Vitamin C and Berberine) and six 
clinically-approved drugs, for metabolically targeting the Doxycycline-resistant 
CSC population (Atovaquone, Irinotecan, Sorafenib, Niclosamide, Chloroquine, and 
Stiripentol). This new combination strategy allows for the more efficacious eradication 
of CSCs with Doxycycline, and provides a simple pragmatic solution to the possible 
development of Doxycycline-resistance in cancer cells. In summary, we propose the 
combined use of i) Doxycycline (Hit-1: targeting mitochondria) and ii) Vitamin C (Hit-
2: targeting glycolysis), which represents a new synthetic-lethal metabolic strategy 
for eradicating CSCs. 
This type of metabolic Achilles’ heel will allow us and others to more effectively 
“starve” the CSC population.
INTRODUCTION
Cancer stem cells (CSCs) are thought to be the 
“root cause” of tumor recurrence, distant metastasis 
and therapy-resistance, driving poor clinical outcome in 
advanced cancer patients [1-3]. Therefore, new therapeutic 
strategies are necessary to identify and eradicate CSCs [4-
7]. As such, this goal remains an unmet medical need. 
Recently, we identified that high mitochondrial 
mass is a new common and characteristic feature of 
CSCs, based on high-resolution proteomics analysis [8-
10]. Importantly, high mitochondrial mass is a surrogate 
marker for increased mitochondrial biogenesis and/or 
elevated mitochondrial protein translation. Thus, this 
simple metabolic observation provides a new means for 
both i) CSC identification [9-13] and ii) CSC eradication 
[9, 10, 14-19]. 
Specifically, we showed that a mitochondrial 
fluorescent dye (MitoTracker) could be effectively used 
for the enrichment and purification of CSC activity from 
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a heterogeneous population of living cells [11-13]. In this 
context, cancer cells with the highest mitochondrial mass 
had the strongest functional ability to undergo anchorage-
independent growth, a characteristic normally associated 
with metastatic potential [11-13]. The ‘Mito-high’ cell 
sub-population also had the highest tumor-initiating 
activity in vivo, as shown using pre-clinical models. 
High mitochondrial mass was strictly correlated with i) 
increased hTERT activity and ii) the ability to undergo cell 
proliferation, which was sensitive to CDK4/6 inhibitors, 
such as palbociclib [16]. Complementary results were 
obtained with other fluorescent mitochondrial probes 
for ROS and hydrogen peroxide, as well as NADH auto-
fluorescence, an established marker of mitochondrial 
“power”/high OXPHOS activity [13].
Moreover, we demonstrated that several classes 
of non-toxic antibiotics could be used to halt CSC 
propagation [14-19]. Because of the conserved 
evolutionary similarities between aerobic bacteria and 
mitochondria, certain classes of antibiotics inhibit 
mitochondrial protein translation, as an off-target 
side-effect [14]. One such group of antibiotics is the 
tetracyclines, the prototypic family member being 
Doxycycline. 
Through this analysis, it became apparent that 
tetracycline antibiotics, such as Doxycycline, could be 
re-purposed to eradicate CSCs, in multiple cancer types 
[14, 20, 21]. These eight distinct cancer types included: 
DCIS, breast (ER(+) and ER(-)), ovarian, prostate, lung, 
and pancreatic carcinomas, as well as melanoma and 
glioblastoma. Doxycycline was also effective in halting 
the propagation of primary cultures of CSCs from breast 
cancer patients, with advanced metastatic disease (isolated 
from ascites fluid and/or pleural effusions) [20]. 
Remarkably, Doxycycline behaves as a strong radio-
sensitizer, successfully overcoming radio-resistance in 
breast CSCs [20]. This has important clinical implications, 
as the majority of ER(+) breast cancer patients are 
currently treated with breast-conserving surgery 
(lumpectomy) plus radiation therapy and hormonal 
therapy with an anti-estrogen. 
Doxycycline is an FDA-approved drug, which 
first became available in 1967, ~50 years ago now. It has 
excellent pharmacokinetic properties, with absorption of 
nearly 100% and a half-life of 18 to 24 hours. However, as 
with any new potential therapy, there is always a concern 
regarding the possible development of drug-resistance. 
Here, we show that cancer cells can indeed 
escape the effects of Doxycycline, by reverting to a 
purely glycolytic phenotype. Fortunately, the metabolic 
inflexibility conferred by this escape mechanism allows 
Doxycycline-resistant (DoxyR) CSCs to be more 
effectively targeted with many other metabolic inhibitors, 
including Vitamin C, which functionally blocks aerobic 
glycolysis. 
Interestingly, previous studies have shown that 
Vitamin C inhibits GAPDH (a glycolytic enzyme) and 
depletes the cellular pool of glutathione, resulting in 
high ROS production and oxidative stress [22]. We show 
here that DoxyR CSCs are between 4- to 10-fold more 
susceptible to the effects of Vitamin C, inhibiting their 
propagation in the range of 100 to 250 µM. Therefore, 
Doxycycline and Vitamin C may represent a new 
synthetic lethal drug combination for eradicating CSCs, 
by ultimately targeting both mitochondrial and glycolytic 
metabolism. 
RESULTS
Metabolic flexibility is the intrinsic ability of a cell to 
change from one carbon fuel source to another; conversely, 
metabolic inflexibility is the exact opposite: the lack of 
ability (or dramatically reduced ability) to change fuel 
sources. It is believed that metabolic flexibility in cancer 
cells allows them to escape therapeutic eradication, leading 
to chemo- and radio-resistance. Here, we used doxycycline 
to pharmacologically induce metabolic inflexibility in 
CSCs, by chronically inhibiting mitochondrial biogenesis. 
This treatment resulted in a purely glycolytic population 
of surviving cancer cells. Then, we identified six other 
clinically-approved therapeutics, two natural products 
and one experimental drug, that all successfully eradicate 
the remaining glycolytic CSCs. Therefore, Doxycycline-
induced metabolic inflexibility may be a practical solution 
to avoiding treatment failure, in a variety of cancer types.
Figure 1: Generating MCF7 DoxyR cells. Doxycycline-
resistant (DoxyR) MCF7 cells were generated by serially 
passaging MCF7 cells, in the presence of increasing step-wise 
concentrations of Doxycycline (12.5, 25 and 50 µM), over a 
period of 9 weeks. See the Materials and Methods section for 
further details. Unless stated otherwise, MCF7 cells resistant 
to 25 µM Doxycycline were utilized for experiments, such as 
unbiased proteomics analysis. 
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Generating a Doxycycline-resistant MCF7 
cell line, to study the potential mechanism(s) 
underlying drug resistance
To study the potential role of Doxycycline-
resistance as an escape mechanism during Doxycycline 
treatment, we created a Doxycycline-resistant MCF7 cell 
line by serially passaging Doxycycline-sensitive MCF7 
cells, in the presence of increasing concentrations of 
Doxycycline (from 12.5 to 50 µM), over a period of 9 
weeks. The experimental procedure we utilized is briefly 
outlined in Figure 1 and is detailed in the Materials and 
Methods section. 
Doxycycline-treated MCF7 cells were analyzed at 
each stage for mitochondrial mass. As shown in Figure 
2A-2D, Doxycycline-resistant (DoxyR) MCF7 cells 
show a significant increase in mitochondrial mass (by 
~1.3- to 1.7-fold), as compared to acute treatment with 
Doxycycline, at the same drug concentration. This overall 
increase in mitochondrial mass was confirmed by immuno-
blot analysis with specific antibodies directed against 
TOMM20, a well-established marker of mitochondrial 
mass (Figure 2E). 
To understand the effects of chronic Doxycycline 
treatment on cell metabolism, we next performed 
metabolic flux analysis with the Seahorse XFe96. 
Interestingly, Figure 3 illustrates that MCF7-DoxyR cells 
show a dramatic reduction in oxygen consumption rates 
(OCR), as compared to matched control MCF7 cells, 
processed in parallel. As a consequence, ATP levels were 
severely depleted. Conversely, glycolysis was substantially 
increased, as measured by the ECAR (extracellular 
acidification rate) (Figure 4). Therefore, DoxyR cells are 
mainly glycolytic. As such, a sub-population of MCF7 
cells survive and develop Doxycycline-resistance, by 
adopting a purely glycolytic phenotype. 
Figure 2: MCF7 DoxyR cells exhibit an increase in mitochondrial mass. A.-D. MCF7 cells were treated with DMSO or 
Doxycycline for acute (48 h) and chronic stimulation (3 weeks), as specified in Materials and Methods, and then mitochondrial mass 
was quantitated by FACS analysis using the probe MitoTracker Deep-Red (640-nm). Note that MCF7 cells chronically treated with 12.5 
µM (A., fold change 1.33), 25 µM (B., fold change 1.68) and 50 µM (C., fold change 1.36) Doxycycline show a significant increase in 
mitochondrial mass compared to MCF7 cells treated with vehicle. Data shown are the mean ± SEM of at least 3 independent experiments 
performed in triplicate. (**) p < 0.01; (***) p < 0.001. D. Representative plots showing increased mitochondrial mass in MCF7 DoxyR cells 
as compared to MCF7 cells. E. Evaluation of the mitochondrial protein TOMM20 in MCF7 and MCF7 DoxyR cells by western blotting. 
Side panel shows densitometric analysis of the blots normalized to β-actin. Data shown are the mean ± SEM of 3 independent experiments. 
(**) p < 0.01.
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Doxycycline-resistant MCF7 cells show an 
increase in CSC markers, but not in functional 
CSC activity, as measured using mammosphere 
assays, proliferation and cell migration
ALDH activity and CD44/CD24 levels are routinely 
used as typical markers to identify breast CSCs [1-7]. 
Interestingly, MCF7-DoxyR cells show a substantial 
increase in these two CSC markers, as revealed by FACS 
analysis (Figure 5). However, these markers do not reflect 
CSC activity. To more directly assess functional CSC 
activity, we used the mammosphere assay. Remarkably, 
MCF7-DoxyR cells show a > 60% reduction in CSC 
activity using the mammosphere assay as a readout 
(Figure 6). Therefore, the increases in CSC markers that 
we observed do not actually reflect a functional increase 
in CSC propagation. 
Consistent with our above findings using the 
mammosphere assay, MCF7-DoxyR cells appear to be 
relatively quiescent, as they show dramatic reductions in 
their ability to proliferate by > 60%, as measured using 
EdU-incorporation, which reflects reduced DNA-synthesis 
(Figure 7A, 7B). Similarly, MCF7-DoxyR cells also show 
a clear defect in cell migration, with a > 50% reduction, as 
observed using the standard “scratch assay” (Figure 7C, 
7D). 
Taken together, these findings are consistent with 
an overall tendency towards a quiescent glycolytic cell 
phenotype. Consistent with this assertion, DoxyR cells 
also show dramatic reductions in ERK-activation and 
AKT-activation, as revealed by immuno-blot analysis, 
with phospho-specific antibody probes (Figure 7E, 7F). 
Figure 3: Mitochondrial respiration is inhibited 
in MCF7 DoxyR cells. The metabolic profile of MCF7 
DoxyR cells monolayers chronically treated with increasing 
concentrations of Doxycycline (12.5 µM ÷ 50 µM), as described 
in Materials and Methods, was assessed using the Seahorse XF-
e96 analyzer. A. Representative tracing of metabolic flux. Dose-
dependent significant reduction in basal respiration, proton 
leak, maximal respiration, ATP levels and spare respiratory 
capacity were observed B. Data shown are the mean ± SEM of 
3 independent experiments performed in sextuplicate. (*) p < 
0.05; (**) p < 0.01; (***) p < 0.001. 
Figure 4: Glycolysis is increased in MCF7 DoxyR 
cells. The metabolic profile of MCF7 DoxyR cells monolayers 
chronically treated with increasing concentrations of 
Doxycycline (12.5 µM ÷ 50 µM), as described in Materials and 
Methods, was assessed using the Seahorse XF-e96 analyzer. A. 
Representative tracing of metabolic flux. B. Dose-dependent 
significant increase in glycolysis and decrease in glycolytic 
reserve as well as glycolytic reserve capacity were observed. 
Data shown are the mean ± SEM of 3 independent experiments 
performed in sextuplicate. (*) p < 0.05; (**) p < 0.01; (***) p 
< 0.001. 
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Proteomics analysis of MCF7-DoxyR cells 
provides validating evidence for a predominantly 
glycolytic phenotype, due to a loss of 
mitochondrial function
In order to further validate our functional 
observations from metabolic flux analysis, we also 
performed unbiased label-free proteomics analysis [8]. 
These results are summarized and presented in Tables 1-5. 
Based on this comprehensive proteomics analysis, MCF7-
DoxyR cells show severe reductions in mitochondrial 
proteins, both those encoded by mitochondrial DNA (mt-
DNA) and those encoded by nuclear DNA (nuc-DNA). 
A loss of mt-DNA-encoded proteins is characteristic 
hallmark of the inhibition of mitochondrial protein 
translation. Therefore, MCF7-DoxyR cells should be 
expected to metabolically phenocopy a mt-DNA-deficient 
genotype (rho(0) cells). For example, the cellular levels 
of MT-ND3, MT-CO2, MT-ATP6 and MT-ATP8 are all 
reduced between 5- to 35-fold (Table 1), which should 
inactivate or impair Complex I, IV and V. Similarly, > 45 
nuclear-encoded mitochondrial proteins, such as NDUFS1, 
NDUFB8 and COX7C, are all decreased between 2- and 
12-fold (Table 1). 
In striking contrast, the levels of 10 glycolytic 
enzymes were all increased between 2- and 7-fold, 
including PGM1, LDHA, ALDOC and GAPDH (Table 
2). Similarly, enzymes associated with glycogen 
metabolism were also increased, between 3- and 4-fold 
(GYS1, PYGM, PYGL); markers of hypoxia were also 
elevated (myoglobin and hemoglobin (alpha/delta)) 
(Table 3), supporting a predominant glycolytic phenotype. 
Consistent with an increase in Aldefluor activity, several 
ALDH gene products were increased, especially 
ALDH1A3. This increased ALDH activity may reflect 
their tendency towards glycolysis, as ALDH isoforms 
contribute significantly to the glycolytic pathway. 
Figure 5: MCF7 DoxyR cells show increased CSC markers. 48h after seeding, MCF7 and MCF7 DoxyR cells were processed for 
the evaluation of ALDEFLUOR activity, an independent marker of CSCs. Each sample was normalized using diethylaminobenzaldehyde 
(DEAB), a specific ALDH inhibitor, as negative control A. The tracing of representative samples is shown B. 48h after seeding, MCF7 
and MCF7 DoxyR cells were re-plated on low-attachment plates, for anoikis assay for 10 hours. Expression of CSC markers (CD24 and 
CD44) was analysed by FACS C. Representative dot plot for the the CD44+/CD24low cell population is shown D. This represents an 
~10-fold increase in ALDH functional activity and a ~3-fold induction of the CD44+/CD24low population. Data are the mean ± SEM of 3 
independent experiments performed in triplicate. (***) p < 0.001. 
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Table 4 shows that 10 mitochondrial ribosomal 
proteins (MRPs) were increased, between 1.5- to 3-fold. 
This would mechanistically explain the compensatory 
increase in mitochondrial mass observed in Figure 2. 
Finally, Table 5 illustrates that 12 cellular ribosomal 
proteins were clearly down-regulated, between 1.8- and 
9-fold, which may drive a severe decrease in cellular 
protein synthesis, due to mitochondrial energy deficits, 
resulting in a relatively quiescent metabolic phenotype. 
A synthetic lethal strategy for eradicating DoxyR 
CSCs, using atovaquone or chloroquine
Thus far, our experimental results indicate 
that DoxyR cells acquire a predominantly glycolytic 
phenotype, to escape the anti-mitochondrial effects of 
Doxycycline. This means that DoxyR cells have been 
inadvertently metabolically synchronized and suffer from 
a type of functional metabolic inflexibility. As such, they 
should be extremely sensitive to additional metabolic 
stressors or perturbations, allowing them to be eliminated 
completely. This immediately suggests a new synthetic 
lethal strategy for the metabolic eradication of CSCs, to 
avoid any resistance to Doxycycline. 
More specifically, if we consider DoxyR as the first 
metabolic Hit in a two-Hit scheme, then DoxyR cells 
should be extremely susceptible to a second metabolic 
Hit. This second metabolic Hit could be achieved by using 
virtually any other “safe” metabolic inhibitors, targeting 
either glycolysis, OXPHOS or autophagy. This two-Hit 
metabolic scheme is illustrated schematically in Figure 8. 
To test this hypothesis, we first used Atovaquone, 
an FDA-approved OXPHOS inhibitor, which targets 
mitochondrial Complex III. Similarly, we examined the 
effects of Chloroquine, a well-known autophagy inhibitor 
[17]. Both Atovaquone and Chloroquine are normally used 
clinically for the treatment and prevention of malaria, a 
parasitic infection. A list summarizing these metabolic 
inhibitors is presented in Figure 9. 
Importantly, Figure 6 shows that DoxyR CSC 
propagation is clearly more sensitive to Atovaquone, as 
compared with control MCF7 CSCs. More specifically, 
treatment with Atovaquone (1 µM) inhibited the CSC 
propagation of the DoxyR cells by > 85%. Previously, 
we showed that the IC-50 for Atovaquone was 1 µM for 
MCF7 CSC propagation [17]. Similarly, Chloroquine 
inhibited their propagation by > 75% at 25 µM and by > 
90% at 50 µM. Thus, it is possible to target the propagation 
of DoxyR CSCs, using existing FDA-approved OXPHOS 
and autophagy inhibitors. 
A synthetic lethal strategy for eradicating DoxyR 
CSCs, using natural products (Vitamin C and 
Berberine) and other FDA-approved drugs
Next, we tested the efficacy of glycolysis inhibitors, 
such as 2-deoxy-glucose (2-DG) and Vitamin C (ascorbic 
acid). Treatment with 2-DG inhibited the propagation of 
DoxyR CSCs by > 90% at 10 mM and 100% at 20 mM 
(Figure 10). In addition, Vitamin C was more potent than 
2-DG; it inhibited DoxyR CSC propagation by > 90% at 
250 µM and 100% at 500 µM (Figure 10). As such, the IC-
50 for Vitamin C in this context was between 100 to 250 
µM, which are within the known achievable blood levels, 
when Vitamin C is taken orally. Previously, we showed 
that the IC-50 for Vitamin C was 1 mM for MCF7 CSC 
propagation [13]. Therefore, DoxyR CSCs are between 4- 
to 10-fold more sensitive to Vitamin C than control MCF7 
CSCs, under identical assay conditions. 
We also examined the efficacy of 4 other clinically-
approved drugs that functionally behave as either 
OXPHOS inhibitors (Irinotecan, Sorafenib, Niclosamide) 
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or glycolysis inhibitors (Stiripentol) (Figure 11). In this 
context, Stiripentol functions as an LDH inhibitor. Their 
rank order potency for inhibiting DoxyR CSC propagation 
is: Niclosamide (IC-50 ~ 100 nM) > Irinotecan (IC-50 ~ 
500 nM) > Sorafenib (IC-50 ~ 0.5 to 1 µM) > Stiripentol 
(IC-50 ~ 10 to 50 µM). 
Finally, we tested the efficacy of Berberine, which 
is a naturally occurring antibiotic that also behaves as 
an OXPHOS inhibitor. It was used as early as 3,000 
B.C. in China, for medicinal purposes. Figure 11 shows 
that treatment with Berberine effectively inhibited the 
propagation of the DoxyR CSCs by > 50% at 1 µM and > 
80% at 10 µM.
DISCUSSION
In this report, we present new functional evidence 
to support a novel synthetic lethal strategy to eradicate 
CSCs. More specifically, we demonstrate that the 
use of Doxycycline, a clinically approved antibiotic, 
induces metabolic stress in cancer cells. This allows the 
remaining cancer cells to be synchronized towards a 
purely glycolytic phenotype, driving a form of metabolic 
inflexibility. This Doxycycline-driven aerobic glycolysis 
was further confirmed and validated, by employing 
high-resolution proteomics analysis and metabolic 
phenotyping. In addition, we discovered that both natural 
products and FDA-approved drugs could be re-purposed 
to eradicate the Doxycycline-resistant CSC population. 
These 9 small molecules included: Vitamin C, Berberine, 
2-DG, Atovaquone, Irinotecan, Sorafenib, Niclosamide, 
Chloroquine, and Stiripentol. 
Our new therapeutic strategy should provide for the 
more efficient eradication of CSCs using Doxycycline, as 
well as a practical means for solving the potential problem 
of Doxycycline resistance in CSCs. As such, we suggest 
a new synthetic lethal strategy for eradicating CSCs, by 
employing i) Doxycycline (to target mitochondria) and ii) 
Vitamin C (to target glycolysis) (Figure 12). Use of this 
combined metabolic strategy should help prevent CSCs 
from exploiting the essential nutrients that they normally 
derive from the tumor microenvironment. 
Chronic Doxycycline treatment functionally 
confers a mitochondrial-deficient metabolic 
phenotype, actively suppressing CSC activity
Previous studies have shown that human cancer 
cells lacking mt-DNA [called rho(0) cells] have largely 
lost their ability to undergo mitochondrial OXPHOS and 
they fail to initiate tumors in vivo, as determined by using 
pre-clinical animal models to assess tumorigenicity [3]. 
Importantly, their ability to undergo OXPHOS and to form 
tumors was effectively restored by genetic replacement of 
their mt-DNA [5]. As such, it appears that mitochondrial 
oxidative function and mt-DNA are required for 
energetically initiating the process of tumorigenesis, 
across multiple cancer types [3, 5].
Here, we observed that MCF7-DoxyR cells strongly 
phenocopy the metabolic behavior of mt-DNA deficient 
(rho(0)) cells, by exhibiting a purely glycolytic phenotype. 
Consistent with this hypothesis, MCF7-DoxyR cells lack 
the expression of four mitochondrial proteins normally 
encoded by mt-DNA (MT-ND3, MT-CO2, MT-ATP6 
and MT-ATP8) and they exhibit a near complete loss of 
OXPHOS activity, with a strong induction of aerobic 
glycolysis. MCF7-DoxyR cells also show significant 
functional reductions in cell proliferation and migration, 
as well as a loss of CSC propagation - a surrogate marker 
Figure 6: Mammosphere formation is inhibited in 
MCF7 DoxyR cells: Targeting DoxyR cells with 
Atovaquone and Chloroquine. Evaluation of mammosphere 
formation in MCF7 and MCF7 DoxyR cells cultured in low 
attachment plates and treated with vehicle or the selective 
OXPHOS inhibitor Atovaquone (ATO) A. or Chloroquine B. 
(which has been shown to impair mitochondrial metabolism), for 
5 days before counting. Note that sphere formation is inhibited 
in MCF7 DoxyR cells as compared to MCF7 cells. In addition, 
mitochondrial-targeting agents like atovaquone and Chloroquine 
were effective in reducing the number of spheres in both MCF7 
and MCF7 DoxyR cells. Data shown are the mean ± SEM of 
3 independent experiments performed in triplicate. (***) p < 
0.001.
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Figure 7: MCF7 DoxyR cells show a quiescent phenotype, with significantly reduced proliferation and cell migration, 
as well as suppression of ERK- and AKT-signaling. Evaluation of cell proliferation by EdU incorporation assay using FACS 
analysis in MCF7 and MCF7 DoxyR cells 48h after seeding A. Note the reduction in EdU positive population in MCF7 DoxyR cells as 
compared to MCF7 cells. The tracing of a representative sample is shown B. Data shown are the mean ± SEM of 4 independent experiments 
performed in triplicate. (***) p < 0.001. Evaluation of cell migration by wound healing assay in MCF7 and MCF7 DoxyR cells which were 
seeded in 6 well plate to create a confluent monolayer. 24h after seeding a wound was created, then cells were washed and incubated at 37° 
C for 24 h. Images were acquired at 0 h and 24 h using Incucyte Zoom (Essen Bioscience). Quantification of cell migration was performed 
using ImageJ software and was expressed as % of wound closure C. Note the low migratory capacity of MCF7 DoxyR cells as compared 
to MCF7 cells. Representative images showing scratch assay D. Bar scale 100 µm. Data shown are the mean ± SEM of 3 independent 
experiments performed in triplicate. (***) p < 0.001. Evaluation of ERK1/2 E. and AKT Ser 473 F. phosphorylation in MCF7 and MCF7 
DoxyR cells by western blotting. Side panels show densitometric analysis of the blots normalized to ERK2 and AKT respectively. Data 
shown are the mean ± SEM of 3 independent experiments. (*) p < 0.05; (**) p < 0.01.
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of tumor-initiating activity. 
Therefore, chronic doxycycline treatment provides a 
pharmacological means to mimic a rho(0) cell phenotype, 
to therapeutically reduce tumor growth and to avoid tumor 
recurrence. However, Doxycycline-resistance still remains 
a valid concern. 
Overcoming resistance to Doxycycline in cancer 
cells, using metabolic inflexibility, synthetic 
lethality and Vitamin C
Resistance to anti-cancer therapy remains as one of 
the key issues in cancer patient management. Treatment 
failure is regarded as an alarming outcome of numerous 
different therapeutic approaches. Indeed, the use of 
combination strategies aimed at hitting multiple aspects of 
tumor progression is currently considered as a promising 
tool to overcome resistance. Mounting evidence suggests 
that CSCs act as the main promoter of tumor recurrence 
and patient relapse [1-5]. Thus, a better understanding of 
the biological and biochemical behavior of CSCs during 
drug resistance may unveil new vulnerabilities, to be 
exploited in a therapeutic setting. 
In this context, our data indicates that a metabolic 
shift from oxidative to glycolytic metabolism represents 
an escape mechanism for breast cancer cells chronically-
treated with a mitochondrial stressor like Doxycycline, as 
Figure 8: A two-hit synthetic lethal strategy for eradicating DoxyR CSCs. Here, we outline a new therapeutic strategy for 
targeting CSCs. Our experimental results indicate that DoxyR cells acquire a predominantly glycolytic phenotype, to escape the anti-
mitochondrial effects of Doxycycline. As such, they should be extremely sensitive to additional metabolic stressors, allowing them to be 
eliminated completely. This immediately suggests a new synthetic lethal strategy for the metabolic eradication of CSCs, to avoid resistance 
to Doxycycline. Specifically, if we consider DoxyR as the first metabolic Hit in a two-Hit scheme, then DoxyR cells should be extremely 
susceptible to a second metabolic Hit. This second metabolic Hit could be achieved by using virtually any other “safe” metabolic inhibitors, 
targeting either glycolysis, OXPHOS or autophagy. 
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mitochondrial dys-function leads to a stronger dependence 
on glucose. 
Our current findings are in line with previous studies 
showing the highly plastic nature of CSCs allows them 
to adjust and adapt their metabolic environment, in order 
to maintain their distinctive properties, in a hostile tumor 
microenvironment, often characterized by an inadequate 
nutrient and oxygen supply (reviewed in [23]). Here, we 
have taken advantage of the glycolytic shift exhibited 
by DoxyR CSCs, as we have used several glycolysis 
inhibitors with the aim to turn their strict metabolic 
inflexibility, into a lethal phenotype. Among the agents 
tested in the our study, Vitamin C has been demonstrated 
to selectively kill cancer cells in vitro and to inhibit 
tumor growth in experimental mouse models [24, 25]. 
Remarkably, many of these actions have been attributed 
to the ability of Vitamin C to act as a glycolysis inhibitor, 
by targeting GAPDH and depleting the NAD pool [22, 
26, 27]. 
In this context, we have previously demonstrated 
that Vitamin C effectively inhibits 3D breast tumor 
spheroid formation, with an IC-50 of 1 mM, suggesting 
that this micronutrient also works as an inhibitor of CSCs 
[13], whose activity is critically dependent on an active 
mitochondrial TCA cycle and OXPHOS. In contrast, 
here we show that DoxyR CSCs are more vulnerable to 
the inhibitory effects of Vitamin C, at 4- to 10-fold lower 
concentrations, between 100 to 250 μM. These findings 
are further supported by clinical studies showing that the 
concurrent use of Vitamin C, with standard chemotherapy, 
reduces tumor recurrence and patient mortality [28, 29]. 
It is worth noting that Vitamin C plasma levels 
Figure 10: Glycolysis inhibitors reduce mammosphere formation in MCF7 DoxyR cells. Evaluation of mammosphere 
formation in MCF7 and MCF7 DoxyR cells cultured in low attachment plates and treated with Vehicle or increasing concentrations of the 
glycoysis inhibitor 2-deoxy-glucose (2 DG) (10 mM to 20 mM) for 5 days before counting A. Mammosphere formation is inhibited in 
MCF7 DoxyR cells cultured in low attachment plates and treated with increasing concentrations of the glycoysis inhibitor Ascorbic Acid 
(100 µM to 500 µM) for 5 days before counting B. Data shown are the mean ± SEM of 3 independent experiments performed in triplicate. 
(***) p < 0.001.
Figure 9: Metabolic inhibitors successfully employed for the eradication of DoxyR CSCs. Briefly, a list of small molecules 
that we successfully used in conjunction with Doxycycline is shown. These include 9 known inhibitors of OXPHOS, glycolysis and 
autophagy. Two natural products (Vitamin C and Berberine), six clinically-approved drugs (Atovaquone, Chloroquine, Irinotecan, 
Sorafenib, Niclosamide, and Stiripentol) and one experimental drug (2-DG), are all highlighted. 
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vary considerably with the route of administration. 
For instance, pharmacokinetic studies performed by 
different research groups have assessed that, after 
oral administration, Vitamin C plasma levels reach 
concentrations of ~70-220 μM [reviewed in reference 
#30], which represents the maximum tolerated oral 
dose. By contrast, Padayatty and co-workers found that, 
compared to oral intake, intravenous administration results 
in 30- to 70- fold higher plasma concentrations of Vitamin 
C [31]. Furthermore, consumption of 5 to 9 servings of 
fruits and vegetables per day allows plasma levels of 
Vitamin C to reach up to 80 μM at steady-state, with 
Figure 11: A panel of clinically-approved drugs inhibits mammosphere formation in MCF7 DoxyR cells. Evaluation of 
mammosphere formation in MCF7 DoxyR cells cultured in low attachment plates and treated with Vehicle or increasing concentrations of 
the LDH inhibitor Stiripentol (2 µM to 100 µM) A. or the OXPHOS inhibitors Irinotecan (500 nM to 80 µM) B., Sorafenib (500 nM to 40 
µM) C., Berberine Chloride (500 nM to 10 µM) D. and Niclosamide E.-F. for 5 days before counting. Data shown are the mean ± SEM of 
3 independent experiments performed in triplicate. (**) p < 0.01: (***) p < 0.001.
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peak values of 220 μM [31]. Remarkably, an intravenous 
infusion of Vitamin C can reach plasma levels of 15,000 
μM (i.e., 15 mM). Interestingly, doses of up to 50 grams 
per day, infused slowly, didn’t exhibit any toxic side 
effects on cancer patients [30]. These observations suggest 
that intravenous administration of Vitamin C may have a 
role in cancer treatment, as this route allows higher plasma 
concentrations than those achievable with the maximum 
tolerated oral dose.
Previous studies have demonstrated that Vitamin C 
behaves as a potent dietary antioxidant, as well as a pro-
oxidant. This pro-oxidant activity results from Vitamin C’s 
action on metal ions, which generates free radicals and 
hydrogen peroxide, and is associated with cell toxicity. Of 
note, it has been shown that high-dose Vitamin C is more 
cytotoxic to cancer cells than to normal cells [32, 33]. 
This selectivity appears to be due to the higher catalase 
content observed in normal cells (~10-100 fold greater), 
as compared to tumor cells. Hence, Vitamin C may be 
regarded as a safe agent that selectively targets cancer 
cells. 
A recent study performed on a panel of cancer cells 
(A431, Panc-1, HeLa, HT29, and MCF7) showed that 
Vitamin C only affects cell viability at concentration of ~3 
to 10 mM [34], thus providing more evidence to support 
a lack of toxicity for low micromolar concentrations of 
Vitamin C. 
Similarly, phase I and II clinical trials, designed to 
deliver high-dose intravenous Vitamin C, have shown a 
lack of toxic side effects for concentrations of up to 292 
μM [35]. Taken together with these findings, our data 
suggest that Vitamin C’s action as a glycolytic inhibitor 
may represent a safe and effective strategy to be used 
in combination therapies, with conventional anticancer 
drugs, as well as with Doxycycline.
Because of our success with 2-DG and Vitamin 
C, we explored additional FDA-approved drugs with 
glycolysis-inhibiting activity that could be repurposed 
to eradicate CSC propagation, in combination with 
Doxycycline. For example, we demonstrated that the LDH 
enzyme inhibitor Stiripentol is also effective at targeting 
DoxyR CSCs; this drug is currently used clinically as an 
anti-epileptic in children. 
We also further explored other suitable metabolic 
approaches to overcome Doxycycline resistance. In this 
context, we evaluated the efficacy of a panel of compounds 
that share the ability to impair mitochondrial function 
(OXPHOS), as a common off-target side-effect. This 
approach was based on the assumption that DoxyR cells, 
which exhibit altered oxidative metabolism, are extremely 
sensitive to the induction of additional mitochondrial 
dysfunction. These effective compounds included four 
FDA-approved drugs, such as Atovaquone, Irinotecan, 
Sorafenib, and Niclosamide, as well as the natural product 
Berberine. 
Interestingly, we observed that Chloroquine also 
reduces the spheroid forming efficiency of DoxyR cells, 
indicating that inhibition of autophagy may represent 
another effective combination strategy, to sensitize breast 
cancer cells to the actions of Doxycycline. 
We believe that the emerging functional relationship 
between metabolism and stemness, also known as 
“metabo-stemness” [36], holds great promise for the future 
of anti-cancer therapy. Thus, our novel findings may pave 
the way for the discovery and validation of more effective 
therapeutic strategies to fully eradicate CSCs, ultimately 
preventing treatment failure and minimizing metastatic 
dissemination. 
Synergistic effects of Doxycycline and Vitamin C 
in the treatment of infectious disease states
Is there any precedent for the use of Doxycycline 
in combination with Vitamin C, in clinical trials? 
Interestingly, another group published a report on a 
randomized clinical trial of the effects of Vitamin C on 
dyspareunia and vaginal discharge, in women receiving 
Doxycycline and Triple sulfa for chlamydial cervicitis 
infections [37]. Importantly, they concluded that the cure 
rate was nearly 5-fold higher in the patients that received 
Vitamin C, together with antibiotic therapy [37]. So, the 
concurrent use of Doxycycline and Vitamin C, in the 
context of this infectious disease, appeared to be highly 
synergistic in patients. 
Similarly, Goc et al., 2016, showed that Doxycycline 
Figure 12: Vitamin C and Doxycycline: A synthetic 
lethal combination therapy for eradicating CSCs. Note 
that both OXPHOS and the glycolytic pathway jointly contribute 
to ATP production. Doxycycline inhibits mitochondrial 
biogenesis and OXPHOS, by acting via mitochondrial ribosomal 
proteins (MRPs); Vitamin C inhibits glycolytic metabolism by 
targeting and inhibiting the enzyme GAPDH. Therefore, their 
use together, as a sequential drug combination, will more 
severely target cell metabolism and energy production, thereby 
preventing or blocking the propagation of CSCs. 
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is synergistic in vitro with certain phytochemicals and 
micronutrients, including Vitamin C, in the in vitro 
killing of the vegetative spirochete form of Borrelia 
spp., the causative agent underlying Lyme disease [38]. 
Vitamin C has also been shown to be synergistic with 
Tetracycline and Chloramphenicol, against the pathogenic 
bacteria, Pseudomonas aeruginosa [39]. However, in 
the above examples, no follow-up mechanistic studies 
were conducted to determine exactly why Doxycycline, 
Tetracycline and Vitamin C were somehow synergistic.
CONCLUSIONS
Numerous functional studies have now directly 
shown that mitochondria are an important new 
therapeutic target in cancer cells [3, 5, 8-21, 40-53]. Since 
Doxycycline, an FDA-approved antibiotic, behaves as an 
inhibitor of mitochondrial protein translation, it may have 
therapeutic value in the specific targeting of mitochondria 
in cancer cells. However, in this paper, we have identified 
a novel metabolic mechanism by which CSCs successfully 
escape from the anti-mitochondrial effects of Doxycycline, 
by assuming a purely glycolytic phenotype. Therefore, 
DoxyR CSCs are then more susceptible to other metabolic 
perturbations, because of their metabolic inflexibility, 
allowing for their eradication with natural products and 
other FDA-approved drugs. Thus, understanding the 
metabolic basis of Doxycycline-resistance has ultimately 
helped us to develop a new synthetic lethal strategy, for 
more effectively targeting CSCs. 
MATERIALS AND METHODS
Materials
Doxycycline, Ascorbic Acid, 2-Deoxy-D-glucose 
(2-DG), Irinotecan, Berberine Chloride, Niclosamide, 
Chloroquine diphosphate, Stiripentol and Atovaquone 
were all purchased from Sigma Aldrich. Sorafenib was 
obtained from Generon. All compounds were dissolved 
in DMSO, except Ascorbic Acid, 2-deoxy-D-glucose (2-
DG) and Chloroquine diphosphate, which were dissolved 
in cell culture medium.
Cell cultures
MCF7 breast cancer cells were obtained from ATCC 
and cultured in DMEM (Sigma Aldrich). MCF-7 cells 
resistant to Doxycycline (MCF7 DoxyR) were selected 
by a stepwise exposure to increasing concentration of 
Doxycycline. In particular, wild type MCF7 cells were 
initially exposed to 12.5 µM Doxycycline and the dose 
gradually increased to 50 µM over a 3-month period. 
The population of resistant cells, named MCF7 DoxyR, 
was selected after 3 weeks of treatment with 12.5 µM 
Doxycycline, followed by 3 weeks of treatment with 25 
µM Doxycycline. MCF7 DoxyR cells were routinely 
maintained in regular medium supplemented with 25 µM 
Doxycycline.
Mammosphere formation
A single cell suspension of MCF7 or MCF7 DoxyR 
cells was prepared using enzymatic (1x Trypsin-EDTA, 
Sigma Aldrich), and manual disaggregation (25 gauge 
needle) [54]. Cells were then plated at a density of 500 
cells/cm2 in mammosphere medium (DMEM-F12/ B27 
/ 20-ng/ml EGF/PenStrep) in nonadherent conditions, in 
culture dishes coated with (2-hydroxyethylmethacrylate) 
(poly-HEMA, Sigma), in the presence of treatments, were 
required. Cells were grown for 5 days and maintained 
in a humidified incubator at 37°C at an atmospheric 
pressure in 5% (v/v) carbon dioxide/air. After 5 days 
for culture, spheres > 50 μm were counted using an 
eye piece graticule, and the percentage of cells plated 
which formed spheres was calculated and is referred to 
as percentage mammosphere formation. Mammosphere 
assays were performed in triplicate and repeated three 
times independently.
Evaluation of mitochondrial mass and function
To measure mitochondrial mass by FACS 
analysis, cells were stained with MitoTracker Deep Red 
(Life Technologies), which localizes to mitochondria 
regardless of mitochondrial membrane potential. Cells 
were incubated with pre-warmed MitoTracker staining 
solution (diluted in PBS/CM to a final concentration of 
10 nM) for 30-60 min at 37 °C. All subsequent steps 
were performed in the dark. Cells were washed in PBS, 
harvested, re-suspended in 300 μL of PBS and then 
analyzed by flow cytometry (Fortessa, BD Bioscience). 
Data analysis was performed using FlowJo software. 
Extracellular acidification rates (ECAR) and real-time 
oxygen consumption rates (OCR) for MCF7 cells were 
determined using the Seahorse Extracellular Flux (XFe-
96) analyzer (Seahorse Bioscience) [15]. Briefly, 15,000 
MCF7 and MCF7 DoxyR cells per well were seeded 
into XFe-96 well cell culture plates for 24h. Then, cells 
were washed in pre-warmed XF assay media (or for OCR 
measurement, XF assay media supplemented with 10mM 
glucose, 1mM Pyruvate, 2mM L-glutamine and adjusted 
at 7.4 pH). Cells were then maintained in 175 µL/well 
of XF assay media at 37C, in a non-CO2 incubator for 1 
hour. During the incubation time, 5 µL of 80mM glucose, 
9 µM oligomycin, and 1 M 2-deoxyglucose (for ECAR 
measurement) or 10µM oligomycin, 9 µM FCCP, 10 µM 
Rotenone, 10 µM antimycin A (for OCR measurement), 
were loaded in XF assay media into the injection ports 
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in the XFe-96 sensor cartridge. Data set was analyzed by 
XFe-96 software after the measurements were normalized 
by protein content (SRB). All experiments were performed 
three times independently.
ALDEFLUOR assay and separation of the ALDH 
positive population
ALDH activity was assessed by FACS analysis 
(Fortessa, BD Bioscence) in MCF7 cells and MCF7 
DoxyR cells. The ALDEFLUOR kit (StemCell 
Technologies) was used to isolate the population with 
high ALDH enzymatic activity. Briefly, 1 × 105 MCF7 and 
MCF7 DoxyR cells were incubated in 1ml ALDEFLUOR 
assay buffer containing ALDH substrate (5 μl/ml) for 40 
minutes at 37°C. In each experiment, a sample of cells 
was stained under identical conditions with 30 μM of 
diethylaminobenzaldehyde (DEAB), a specific ALDH 
inhibitor, as a negative control. The ALDEFLUOR-
positive population was established in according to the 
manufacturer’s instructions and was evaluated in 3 × 104 
cells. Data analysis was performed using FlowJo software.
Anoikis assay
MCF7 and MCF7 DoxyR cells were seeded on 
low-attachment plates to enrich for the CSC population 
[54]. Under these conditions, the non-CSC population 
undergoes anoikis (a form of apoptosis induced by a lack 
of cell-substrate attachment) and CSCs are believed to 
survive. The surviving CSC fraction was analyzed by 
FACS analysis. Briefly, 1 x 105 MCF7 and MCF7 DoxyR 
monolayer cells were seeded for 48h in 6-well plates. 
Then, cells were trypsinized and seeded in low-attachment 
plates in mammosphere media. After 10h, cells were 
spun down and incubated with CD24 (IOTest CD24-PE, 
Beckman Coulter) and CD44 (APC mouse Anti-Human 
CD44, BD Pharmingen) antibodies for 15 minutes on ice. 
Cells were rinsed twice and incubated with LIVE/DEAD 
dye (Fixable Dead Violet reactive dye; Life Technologies) 
for 10 minutes. Samples were then analyzed by FACS 
(Fortessa, BD Bioscence). Only the live population, as 
identified by the LIVE/DEAD dye staining, was analyzed 
for CD24/CD44 expression. Data were analyzed using 
FlowJo software.
Label-free semi-quantitative proteomics analysis
Cell lysates were prepared for trypsin digestion 
by sequential reduction of disulphide bonds with TCEP 
and alkylation with MMTS. Then, the peptides were 
extracted and prepared for LC-MS/MS. All LC-MS/MS 
analyses were performed on an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, CA) coupled to 
an Ultimate 3000 RSLC nano system (Thermo Scientific, 
formerly Dionex, The Netherlands). Xcalibur raw data 
files acquired on the LTQ-Orbitrap XL were directly 
imported into Progenesis LCMS software (Waters Corp., 
Milford, MA, formerly Non-linear dynamics, Newcastle 
upon Tyne, UK) for peak detection and alignment. Data 
were analyzed using the Mascot search engine. Five 
technical replicates were analyzed for each sample type 
[8, 12]. 
Immuno-blot analysis
MCF7 and MCF7 DoxyR cells protein lysates 
were electrophoresed through a reducing SDS/10% (w/v) 
polyacrylamide gel, electroblotted onto a nitrocellulose 
membrane and probed with primary antibodies against 
phosphorylated AKT (Ser 473) and ATK (Cell Signaling), 
Phopshorylated ERK 1/2 (E-4), ERK2 (C-14), TOMM20 
(F-10) and β-actin (C2), all purchased from Santa Cruz 
Biotechnology. Proteins were detected by horseradish 
peroxidase-linked secondary antibodies and revealed using 
the SuperSignal west pico chemiluminescent substrate 
(Fisher Scientific).
Click-iT EdU proliferation assay
48h after seeding MCF7 and MCF7 DoxyR 
were subjected to proliferation assay using Click-
iT Plus EdU Pacific Blue Flow Cytometry Assay Kit 
(Life Technologies), customized for flow cytometry. 
Briefly, cells were treated with 10 µM EdU for 2 hours 
and then fixed and permeabilized. EdU was detected 
after permeabilization by staining cells with Click-
iT Plus reaction cocktail containing the Fluorescent 
dye picolylazide for 30 min at RT. Samples were then 
washed and analyzed using flow cytometer (Fortessa, 
BD Bioscence). Background values were estimated by 
measuring non-EdU labeled, but Click-iT stained cells. 
Data were analyzed using FlowJo software. 
Migration assay
MCF7 and MCF7 DoxyR cells were allowed to 
grow in regular growth medium until they were 70-80 % 
confluent. Next, to create a scratch of the cell monolayer, 
a p200 pipette tip was used. Cells were washed twice with 
PBS and then incubated at 37° C in regular medium for 
24h. The migration assay was evaluated using Incucyte 
Zoom (Essen Bioscience) [55]. The rate of migration was 
measured by quantifying the % of wound closure area, 
determined using the software ImageJ, according to the 
formula:




Data is represented as the mean ± standard error of 
the mean (SEM), taken over ≥ 3 independent experiments, 
with ≥ 3 technical replicates per experiment, unless 
otherwise stated. Statistical significance was measured 
using the t-test. P ≤ 0.05 was considered significant.
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